BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30257705)

  • 1. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
    Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
    Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal Cancer.
    Jiang G; Luo C; Sun M; Zhao Z; Li W; Chen K; Fan T
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):710-714. PubMed ID: 27754705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
    Ikehata M; Ueda K; Iwakawa S
    Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level.
    Huang D; Xiao F; Hao H; Hua F; Luo Z; Huang Z; Li Q; Chen S; Cheng X; Zhang X; Fang W; Hu X; Liu F
    Cell Commun Signal; 2020 Oct; 18(1):169. PubMed ID: 33109187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor.
    Deng G; Song GA; Pong E; Sleisenger M; Kim YS
    Cancer Res; 2004 Apr; 64(8):2692-8. PubMed ID: 15087381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.
    Fetahu IS; Höbaus J; Aggarwal A; Hummel DM; Tennakoon S; Mesteri I; Baumgartner-Parzer S; Kállay E
    Int J Cancer; 2014 Nov; 135(9):2014-23. PubMed ID: 24691920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of CDX2 expression in colon cancer via a dominant repression pathway.
    Hinoi T; Loda M; Fearon ER
    J Biol Chem; 2003 Nov; 278(45):44608-16. PubMed ID: 12947088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
    Zhang Y; Fatima N; Dufau ML
    Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
    Yamada N; Hamada T; Goto M; Tsutsumida H; Higashi M; Nomoto M; Yonezawa S
    Int J Cancer; 2006 Oct; 119(8):1850-7. PubMed ID: 16721789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
    Bond CE; Bettington ML; Pearson SA; McKeone DM; Leggett BA; Whitehall VL
    BMC Cancer; 2015 Jan; 15():20. PubMed ID: 25613750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
    Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
    J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.